Yahoo
    • Mail
    • Straits Times Index3,166.30+0.24%
    • Nikkei31,524.22+1.21%
    • Hang Seng18,949.94+4.02%
    • FTSE 1007,577.18+1.16%
    • Bitcoin USD27,102.48+0.68%
    • CMC Crypto 200604.85+0.45%
    • S&P 5004,258.27+0.88%
    • Dow33,324.46+0.80%
    • Nasdaq13,237.61+1.04%
    • Gold1,990.10-0.27%
    • Crude Oil72.13+2.90%
    • 10-Yr Bond3.6310+0.64%
    • FTSE Bursa Malaysia1,381.26-0.13%
    • Jakarta Composite Index6,633.26-0.05%
    • PSE Index6,512.01+1.27%
    Explore/

    Biotech and drug stocks

    Biotech and drug stocks

    7.09k followers • 31 symbols Watchlist by Yahoo Finance

    Follow this list to discover and track large drug and biotechnology companies.

    31 symbols

    • LLY439.523.03%

      Eli Lilly and Company

    • JNJ154.590.05%

      Johnson & Johnson

    • NVO155.46-2.52%

      Novo Nordisk A/S

    • MRK110.80-0.13%

      Merck & Co., Inc.

    • RHHBY39.970.38%

      Roche Holding AG

    • ABBV134.210.77%

      AbbVie Inc.

    • AZN72.940.10%

      AstraZeneca PLC

    • PFE38.290.26%

      Pfizer Inc.

    • NVS98.231.12%

      Novartis AG

    • BMY64.68-

      Bristol-Myers Squibb Company

    • SNY50.730.27%

      Sanofi

    • AMGN213.30-0.97%

      Amgen Inc.

    • GILD76.00-0.21%

      Gilead Sciences, Inc.

    • VRTX323.25-0.37%

      Vertex Pharmaceuticals Incorporated

    • REGN728.63-2.54%

      Regeneron Pharmaceuticals, Inc.

    • ZTS167.421.41%

      Zoetis Inc.

    • GSK33.960.16%

      GSK plc

    • BAYRY13.98-

      Bayer Aktiengesellschaft

    • TAK16.130.23%

      Takeda Pharmaceutical Company Limited

    • MRNA129.831.31%

      Moderna, Inc.

    • BIIB298.77-3.64%

      Biogen Inc.

    • HLN8.270.12%

      Haleon plc

    • SGEN194.720.05%

      Seagen Inc.

    • BNTX107.733.61%

      BioNTech SE

    • GMAB39.16-0.18%

      Genmab A/S

    • ALNY190.531.86%

      Alnylam Pharmaceuticals, Inc.

    • HZNP99.95-0.45%

      Horizon Therapeutics Public Limited Company

    • ARGX396.211.55%

      argenx SE

    • BMRN88.710.45%

      BioMarin Pharmaceutical Inc.

    • RPRX33.380.21%

      Royalty Pharma plc

    • Motley Fool

      Why Biohaven Stock Caught Fire This Week

      Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

    • Motley Fool

      3 High-Quality Dividend Stocks Yielding 3% to Buy in June

      Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.

    • Reuters

      Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

      Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.Kisqali was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone.

    • PR Newswire

      Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting

      Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023. Presentations include new analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast canc

    • GlobeNewswire

      Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

      Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv

    • Reuters

      UPDATE 1-BioNTech's OncoC4 partnership off to good start with mid-stage trial results

      BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial. The experimental drug, known as gotistobart, was tested on patients with metastatic non-small cell lung cancer which could no longer be helped by a group of so-called checkpoint inhibitor drugs such as Merck & Co's Keytruda. A follow-on trial in the third and last phase of testing typically required for approval would start in the third quarter of this year, BioNTech added in its statement.

    • Zacks

      Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies

      Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.

    • Simply Wall St.

      Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 78% of the company

      Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...

    • Simply Wall St.

      Possible Bearish Signals With Amgen Insiders Disposing Stock \

      Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...

    • GlobeNewswire

      BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

      BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL

    • American City Business Journals

      The area's largest life sciences employer, Takeda keeps reinventing itself

      Takeda is doubling down on research and development in the Boston area with a host of new drugs in development for rare diseases, cancer, dengue and Covid-19.

    • Motley Fool

      Better Healthcare AI Stock: Moderna vs. Doximity

      The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.

    • Motley Fool

      3 Nasdaq 100 Stocks That Are Surefire Buys in June

      These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.

    • Zacks

      The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

      NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.

    • Simply Wall St.

      Does The Market Have A Low Tolerance For Haleon plc's (LON:HLN) Mixed Fundamentals?

      With its stock down 8.9% over the past month, it is easy to disregard Haleon (LON:HLN). We, however decided to study...

    • Zacks

      Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

      Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.

      • Paccar (PCAR) Outpaces Stock Market Gains: What You Should Know
        Zacks
      • 3M (MMM) Outpaces Stock Market Gains: What You Should Know
        Zacks
    • The Wall Street Journal

      Medicare Plans to Cover Alzheimer’s Drugs

      Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer. The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works. Most Alzheimer’s patients in the U.S. are Medicare enrollees.

    • Reuters

      UPDATE 1-J&J secures dismissal of whistleblower case over misuse of confidential info

      A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.

    • Investor's Business Daily

      Is Pfizer Stock A Buy As It Leaps Into The Red-Hot Weight-Loss Race?

      Is Pfizer stock a buy after the company unveiled promising weight-loss results for its diabetes pill? Is PFE stock a buy or a sell right now?

    • Investopedia

      Dow Jones Today: Debt Vote Drives Index Higher

      The Dow Jones Industrial Average moved higher by more than 0.5%, or 153 points, as investors celebrated the House of Representatives passage of the debt-ceiling bill, which now goes to the Senate.

    • Zacks

      Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

      Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).

    • Reuters

      J&J secures dismissal of whistleblower case over misuse of confidential info

      A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.

    • Reuters

      REFILE-J&J secures dismissal of whistleblower case over misuse of confidential info

      A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.

    • Investor's Business Daily

      Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

      Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

    • Investor's Business Daily

      Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High

      Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.

    Finance
    • Cryptocurrencies
    • News
    • Property
    • Money
    • Markets
    • Industries
    • Watchlists
    • My Portfolio
    • All Markets Summit
    • My Screeners